FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents

Interleukin

Interleukin patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

Related Categories:

Drug, Bio-affecting And Body Treating Compositions


Lymphokine > Interleukin



Methods for autologous stem cell transplantation
12/18/14 - 20140369955 - Materials and methods for obtaining populations of lymphocytes and administering the population of lymphocytes to a subject are disclosed herein. In particular, disclosed herein are materials and methods for obtaining lymphocyte populations that contain at least about 0.5×109 NK cells per kilogram weight of the subject from which the cells...

Conjugates of gm-csf and il-7, compositions and methods related thereto
12/18/14 - 20140369956 - In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-7 and uses related thereto, e.g., enhancing the adaptive immune system. Typically the GM-CSF and IL-7 are connected by a polymer linker, e.g., polypeptide. In certain embodiments, the disclosure relates to nucleic acids encoding these polypeptide conjugates, vectors comprising...

Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, immunoglobulins and chemotactic factors
12/18/14 - 20140369957 - The present invention refers to a combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins C3a/C4a, immunoglobulins and chemotactic factors. The invention also relates to a process for the preparation of said combination from serum, placenta or colostrum and to composition containing said combination for use...

Il-12 for radiation protection and radiation-induced toxicity mitigation
12/18/14 - 20140369958 - Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising inter-leukin 12 (IL-12) useful for treating radiation-induced damage in a subject. In particular, the instant disclosure provides methods and compositions for radiation protection and/or radiation toxicity mitigation for the treatment of acute radiation syndrome and radiation induced...

Formulation having mobilizing activity
12/11/14 - 20140363394 - The present innovation relates to a novel formulation capable of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the formulation is characterized in that it contains defibrotide in combination with at least one haematopoietic factor having the capacity to mobilize...

Adoptive cell therapy with specific regulatory lymphocytes
12/04/14 - 20140356318 - The present invention comprises a method of treatment of an autoimmune disease involving a specific tolerance induction (“STI”) event, wherein the method includes: collecting a first sample from the patient prior to the STI event; detecting an STI event or performing a procedure that correlates in time to an STI...

Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases
12/04/14 - 20140356319 - The present invention describes peptides comprising phycocyanobilin (PCB), as well as the medical use of said peptides and that of PCB, due to the neuroprotector and/or neuroregenerative effects identified for them. Furthermore, pharmaceutical combinations of said peptides and of PCB with proteins or other peptides with synergic effect justify their...

Polyoma virus jc peptides and proteins in vaccination and diagnostic applications
12/04/14 - 20140356320 - The present invention relates to the field of vaccination or immunization, in particular therapeutic vaccination, and diagnosis. Pharmaceutical compositions and kits capable of eliciting a protective immune response against polyoma virus JC (JCV) are disclosed, which may be used e.g., for therapy or for prevention of progressive multifocal leukoencephalopathy (PML)...

Materials and methods for treatment of liver cancer
12/04/14 - 20140356321 - Granulin-epithelin precursor (GEP), a pluripotent growth factor, is a hepatic oncofetal protein defining a cancer stem cell (CSC) population in liver cancer. The present invention provides the use of GEP inhibitors (including anti-GEP antibody) for inhibiting immune evasion by liver cancer cells and for eliminating liver cancer stem cells....

Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
12/04/14 - 20140356322 - The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on...

Compositions and methods for soft tissue augmentation
12/04/14 - 20140356323 - The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation....

Method of enhanced antibiotic activity via chemotaxis
11/27/14 - 20140348780 - Compositions and methods for treating infectious diseases produced by biofilms are disclosed. More specifically, the present disclosure refers to a pharmaceutical compositions which may be used for treating biofilm infections, specifically, biofilms formed by bacteria such as Pseudomonas, E. coli, Klebsiella, and other human pathogens. Pharmaceutical compositions may include a...

Conjugates of gm-csf and il-9, compositions and methods related thereto
11/27/14 - 20140348781 - In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-9 and uses related thereto, e.g., enhancing the adaptive immune system. Typically the GM-CSF and IL-9 are connected by a polymer linker, e.g., polypeptide. In certain embodiments, the disclosure relates to nucleic acids encoding these polypeptide conjugates, vectors comprising...

Vaccine immunotherapy for immune suppressed patients
11/27/14 - 20140348782 - A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive T-cells and exposing the naive T-cells to endogenous or exogenous antigens at an appropriate site....

Vaccine immunotherapy for immune suppressed patients
11/27/14 - 20140348783 - A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive T-cells and exposing the naive T-cells to endogenous or exogenous antigens at an appropriate site....

Compositions and methods for treatment of angiogenesis in pathological lesions
11/27/14 - 20140348784 - Treatment of lesions of pathological angiogenesis, especially tumors, rheumatoid arthritis, diabetic retinopathy, age-related muscular degeneration, and angiomas. A conjugate is used comprising a molecule that exerts a biocidal or cytotoxic effect on target cells in the lesions and an antibody directed against an extracellular matrix component which is present in...

Neutralizing gp41 antibodies and their use
11/27/14 - 20140348785 - Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies...

Beta-mannosylceramide and stimulation of nkt cell anti-tumor immunity
11/27/14 - 20140348786 - β-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of α-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising β-mannosylceramide, as...

Purified proteins
11/20/14 - 20140341843 - The present invention provides methods and compositions for the preparation and delivery of chimeric cytokine proteins, including cell cultures, methods of purification and purified compositions....

Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer
11/20/14 - 20140341844 - This invention relates to the treatment of cancer using anti-ErbB antibodies, such as cetuximab or trastuzumab, in combination with antibody-interleukin 2 (IL2) conjugates which target tenascin-C....

Methods and systems for treating cell proliferation related disorders
11/20/14 - 20140341845 - and a kit for performing the method, a computer implemented system for performing the method, a pharmaceutical composition useful in the method and a method for causing an autovaccine effect in a subject using the method....

Methods of inhibiting photoreceptor apoptosis
11/20/14 - 20140341846 - The present invention provides methods to prevent photoreceptor death. In particular, the present invention provides peptides which prevent FAS-mediated photoreceptor apoptosis....

Drug delivery product and methods
11/13/14 - 20140335047 - The present invention provides a particulate delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload molecule and a payload trapping molecule. The invention further provides methods of making and methods of using the particulate delivery system....

7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of using the same in combination therapy
11/13/14 - 20140335048 - or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially....

Quil a fraction with low toxicity and use thereof
11/13/14 - 20140335049 - Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise...

Conjugates of an il-2 moiety and a polymer
11/06/14 - 20140328791 - Conjugates of an IL-2 moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the nonpeptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, methods of administering compositions to an individual, nucleic acid sequences, expression...

Methods and compositions for treating and preventing viral infections
11/06/14 - 20140328792 - A method of treating or preventing a systemic viral infection in a mammal by administering a pharmaceutically acceptable composition selected from the group consisting of squalamine, an active isomer thereof, and an active analogue thereof, via a dosing regimen that delivers effective antiviral concentrations of squalamine. Also compositions for achieving...

Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
11/06/14 - 20140328793 - Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the...

Anti-il-6 vaccine composition
10/30/14 - 20140322161 - The present invention relates to a pharmaceutical composition comprising, by way of active ingredient, at least one polypeptide comprising, or constituted by a sequence constituted by at least 8 contiguous amino acids and from at the most 30 contiguous amino acids chosen from within the interleukin-6 sequence and from at...

Use of ferritin to treat iron disorders
10/30/14 - 20140322162 - Methods and compositions for treating an iron disorder in a patient are presented, including methods for orally administering a recombinant yeast that produces H-ferritin-iron complex or the H-ferritin-iron complex extracted from the yeast. Data indicate that administration of the recombinant yeast more effectively increases hemoglobin, hematocrit and transferrin saturation than...

Neutralizing antibodies to hiv-1 and their use
10/30/14 - 20140322163 - Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic...

Il-2 derivatives polypeptides with agonist activity for therapy of cancer and chronic infections
10/23/14 - 20140314709 - The present invention relates to polypeptides which share primary sequence with human IL-2, except for several amino acids that have been mutated. The mutations introduced substantially reduce the ability of these polypeptides to stimulate in vitro and in vivo regulatory T cells (T CD4+CD25+FoxP3+) and make them more effective in...

Il-12 p40 monomer, monoclonal antibody against p40 homodimer and the combination of the two for autoimmune disease treatment
10/23/14 - 20140314710 - A novel approach to discover new drugs against MS and other autoimmune diseases is disclosed. The p40 family of cytokines has four members which include interleukin-12 (IL-12), the p40 monomer (p40), the p40 homodimer (p402), and the IL-23. To facilitate the studies on p402 and p40, neutralizing monoclonal antibodies (mAb)...

Il-22 polypeptides and il-22 fc fusion proteins and methods of use
10/23/14 - 20140314711 - The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof....

Fusion protein comprising an interleukin 4 and interleukin
10/23/14 - 20140314712 - The invention is concerned with a fusion protein comprising interleukin 10 and interleukin 4, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing...

Use of inclusion bodies as therapeutic agents
10/16/14 - 20140308237 - The present invention relates to the use of inclusion bodies as vehicles for therapeutic protein delivery. This method is applicable to the delivery of therapeutic proteins to intracellular locations. In addition, the invention also relates to the administration of a cell or a pharmaceutical composition comprising inclusion bodies formed by...

Immunomodulating compositions and methods of use thereof
10/16/14 - 20140308238 - The invention is directed to β1-6 glucans, compositions, diagnostic kits, and devices comprising the same, and methods of use thereof in modulating immune response and treating, delaying progression of, reducing the incidence or severity of cancer, infection, inflammation, and autoimmune diseases. The β1-6 glucans of certain embodiments of the invention...

Chimeric cytokine formulations for ocular delivery
10/16/14 - 20140308239 - Featured herein are vehicle formulations and formulations containing a chimeric cytokine designed for e.g., ocular delivery....

Therapeutic agent for infections, and treatment method using same
10/16/14 - 20140308240 - (Means for Solving Problems) The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of...

Biomarkers for t cell malignancies and uses thereof
10/16/14 - 20140308241 - Described are biomarkers including TOX useful for the diagnosis or prognosis of T cell malignancy. A level of a biomarker is determined in a sample from a subject and compared to a control level, wherein an increased level of the biomarker in the sample relative to the control level indicates...

Extended recombinant polypeptides and compositions comprising same
10/09/14 - 20140301974 - The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and...

Methods for treating blood disorders
10/09/14 - 20140301975 - Methods of treating blood disorders are described....

Novel hydroxamates as therapeutic agents
10/09/14 - 20140301976 - The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also...

Overload and elute chromatography
10/09/14 - 20140301977 - The present invention provides methods for purifying a polypeptide from a composition comprising the polypeptide and at least one contaminant by overloading a chromatography material and eluting the product....

Light chain immunoglobulin fusion proteins and methods of use thereof
10/02/14 - 20140294758 - Provided are recombinant antibodies comprising one or more peptides fused to the C-terminus of the light chain constant region. Recombinant immunocytokines comprising a cytokine fused to the C-terminus of the light chain constant region are described and shown to be surprisingly active....

Targeting regulatory t cells with heterodimeric proteins
10/02/14 - 20140294759 - The present invention relates to methods and compositions for modulating T cells. The modulation includes suppressing or inducing regulatory T cells or cytotoxic T cells....

Novel cell and therapeutical and diagnostical methods based thereon
10/02/14 - 20140294760 - The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to methods for screening...

Treatments for migraine and related disorders
10/02/14 - 20140294761 - Embodiments are directed to compositions and methods of treating migraine and related neurological disorders. In certain aspects, methods and compositions are for reducing cortical spreading depression and/or suppressing the neurochemical basis for chronic and acute migraine events, and provide methods and pharmaceutical compositions related to both acute and preventive therapies...

Glycopegylation methods and proteins/peptides produced by the methods
10/02/14 - 20140294762 - The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide....

Peptidomimetic protease inhibitors
10/02/14 - 20140294763 - The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds...

Compounds and compositions used to epigenetically transform cells and methods related thereto
10/02/14 - 20140294764 - This disclosure relates to compounds, compositions and methods of epigenetically transforming cells. In certain embodiments, the disclosure relates to methods of generating epigenetically altered cells comprising mixing isolated cells with compositions disclosed herein under conditions such that epigenetically altered cells are formed. In certain embodiments, the disclosure contemplates inducing cells,...

Lsr antibodies, and uses thereof for treatment of cancer
10/02/14 - 20140294765 - This invention relates to antibodies and antigen binding fragments and conjugates containing same, and/or alternative scaffolds, specific for LSR molecules, which are suitable drugs for immunotherapy and treatment of specific cancer....

Molecular diagnostic panel of eosinophilic gastrointestinal disorders
09/25/14 - 20140286896 - Embodiments of the invention are directed to methods of diagnosing eosinophilic gastritis (EG), or remission therefrom in a subject, wherein the methods include applying a sample from the subject to a diagnostic panel that contains selected markers for EG, analyzing the results thereof, and making a determination as to the...

Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein
09/25/14 - 20140286897 - Compositions comprising TL1A-Ig fusion proteins and methods of their use, e.g., for the treatment of diseases and disorders associated with antigen-specific immune responses, are described. Also described are combination therapies that include the administration of a TNFRSF25 agonist and an interleukin (e.g., IL-2) and/or an mTOR inhibitor (e.g., rapamycin)....

Interleukin-2 muteins for the expansion of t-regulatory cells
09/25/14 - 20140286898 - Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also,...

Novel use of members of il-10 cytokine family
09/18/14 - 20140271539 - The invention relates to a novel use of the members of the IL-10 cytokine family in wound healing. Particularly, the invention relates to the use of the member of the IL-10 cytokine family in the promotion of the proliferation and the migration of keratinocyte cells in wound healing....

7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one, salts thereof and methods of using the same in combination therapy
09/18/14 - 20140271540 - or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially....

Compounds and pharmaceutical compositions for the treatment of viral infections
09/11/14 - 20140255339 - Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents....

Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid
09/11/14 - 20140255340 - The invention relates to a stable amorphous form of (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid and its use in the treatment of conditions mediated by the action of PGD2 at the CRTH2 receptor....

Tumor selective chemokine modulation
09/11/14 - 20140255341 - Therapies effective for the treatment and prevention of cancer and other diseases are disclosed. These methods include the administration of therapeutically effective amounts of agents that increase the local production of effector cell-attracting chemokines within tumor lesions, with concomitant suppression of local production of undesirable chemokines that attract regulatory T(reg)...

Thiophene derivatives
09/11/14 - 20140255342 - R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the present application....

Dna vaccine, method of inducing the immune response, method of immunisation, antibodies specifically recognising the h5 haemagglutinin of an influenza virus and use of the dna vaccine
09/11/14 - 20140255343 - The object of the invention is a DNA vaccine, method of inducing the immune response, antibodies specifically recognising the haemagglutinin H5 of an influenza virus and application of the DNA vaccine. According to the invention, one or two-fold immunisation of hens with DNA vaccine containing a cDNA encoding the modified...

Methods of use for il-22 promoting rejuvenation of thymic and bone marrow function
09/04/14 - 20140248235 - The present invention provides methods and compositions for the use of IL-22 to promote thymic growth following thymic insult. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22 compositions for treating patients with thymic atrophy and alterations in bone marrow derived white blood cells, including cancer...

Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction
09/04/14 - 20140248236 - The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes....

Multimeric il-15 soluble fusion molecules and methods of making and using same
08/28/14 - 20140242025 - The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor α/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus)....

Compounds, compositions, and methods for preventing metastasis of cancer cells
08/28/14 - 20140242026 - Disclosed are methods for preventing metastasis of cancer cells. The disclosed compounds can be used to prevent the spread of tumor or other types of cancer cells....

Purine nucleoside analogues for treating flaviviridae including hepatitis c
08/21/14 - 20140234251 - This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine. The optionally substituted pentofuranonucleoside, or a...

Composition and methods for the treatment of degenerative retinal conditions
08/21/14 - 20140234252 - The present invention is directed to compositions and methods for the treatment of degenerative retinal conditions. According to a general aspect, the present invention is directed to inflammatory mediators, preferably components or substrates of the NLRP3-inflammasome, for use in the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation....

Methods of treating multiple myeloma and resistant cancers
08/14/14 - 20140227221 - Erastin analogs are useful in treating various cancers, particularly multiple myeloma. Erastin analogs are also useful in treating cancers that are resistant to other anticancer agents....

Cyclin dependent kinase inhibitors and methods of use
08/14/14 - 20140227222 - The presently disclosed subject matter relates to methods and compositions for protecting healthy cells from damage due to DNA damaging agents. In particular, the presently disclosed subject matter relates to the protective action of selective cyclin dependent kinase 4/6 (CDK4/6) inhibitors administered to subjects that have been exposed to or...

Pegylated interleukin-10
08/14/14 - 20140227223 - Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus...